Developing novel product candidates for respiratory viral diseases & cancer
A clinical stage company aiming to address unmet medical needs in respiratory viral diseases and cancer
Traws Pharma leverages broad and deep expertise in small molecule chemistry, artificial intelligence and machine learning, rational drug design & streamlined development to deliver innovative medicines. We target critical threats to human health, aiming to overcome problems caused by acquired resistance to current medications, with an additional focus on vulnerable populations
Traws Pharma Provides Business Update and Reports Q3 2024 Financial
Results
Traws Pharma, Inc. today outlined recent business updates and reported unaudited financial results for the third quarter ended September 30, 2024.
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Traws Pharma, Inc. today announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir).